BR9913138A - Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer - Google Patents

Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer

Info

Publication number
BR9913138A
BR9913138A BR9913138-2A BR9913138A BR9913138A BR 9913138 A BR9913138 A BR 9913138A BR 9913138 A BR9913138 A BR 9913138A BR 9913138 A BR9913138 A BR 9913138A
Authority
BR
Brazil
Prior art keywords
useful
quinolin
formula
agents against
mammals
Prior art date
Application number
BR9913138-2A
Other languages
English (en)
Other versions
BR9913138B1 (pt
BRPI9913138B8 (pt
Inventor
Susan Deborah La Greca
Joseph Peter Lyssikatos
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9913138A publication Critical patent/BR9913138A/pt
Publication of BR9913138B1 publication Critical patent/BR9913138B1/pt
Publication of BRPI9913138B8 publication Critical patent/BRPI9913138B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE QUINOLIN-2-ONA SUBSTITUìDOS COM ALQUINILA úTEIS COMO AGENTES CONTRA O CâNCER"<D>. A presente invenção refere-se a composto da fórmula 1 e a seus sais, pró-drogas e solvatos farmaceuticamente aceitáveis, em que R¹, R², R^ 4^, R^ 5^, R^ 6^, R^ 7^, R^ 8^, R^ 9^, R^ 10^ e R^ 11^ são tais como aqui se definem. Os composto acima da fórmula 1 são úteis no tratamento de distúrbios hiperproliferativos, tais como câncer, em mamíferos. A invenção também refere-se a composições farmacêuticas que contêm compostos da fórmula 1 e a métodos para a inibição do crescimento anormal das células, incluindo o câncer, em mamíferos, pela administração de compostos da fórmula 1, a mamíferos que tenham necessidade de tal tratamento.
BRPI9913138A 1998-08-27 1999-08-06 derivado de quinolin-2-ona substituído com alquinila e composição farmacêutica contendo o mesmo BRPI9913138B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9814598P 1998-08-27 1998-08-27
PCT/IB1999/001398 WO2000012499A1 (en) 1998-08-27 1999-08-06 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents

Publications (3)

Publication Number Publication Date
BR9913138A true BR9913138A (pt) 2001-05-08
BR9913138B1 BR9913138B1 (pt) 2013-11-05
BRPI9913138B8 BRPI9913138B8 (pt) 2016-05-17

Family

ID=22267481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9913138A BRPI9913138B8 (pt) 1998-08-27 1999-08-06 derivado de quinolin-2-ona substituído com alquinila e composição farmacêutica contendo o mesmo

Country Status (40)

Country Link
US (3) US6150377A (pt)
EP (1) EP1107963B1 (pt)
JP (1) JP3495706B2 (pt)
KR (1) KR20010072991A (pt)
CN (1) CN1314904A (pt)
AP (1) AP2001002079A0 (pt)
AT (1) ATE321037T1 (pt)
AU (1) AU4925499A (pt)
BG (1) BG105365A (pt)
BR (1) BRPI9913138B8 (pt)
CA (2) CA2578326C (pt)
CO (1) CO5130017A1 (pt)
CZ (1) CZ2001660A3 (pt)
DE (1) DE69930518T2 (pt)
DZ (1) DZ2880A1 (pt)
EA (1) EA200100135A1 (pt)
EE (1) EE200100118A (pt)
ES (1) ES2259237T3 (pt)
GE (1) GEP20033001B (pt)
GT (1) GT199900140A (pt)
HK (1) HK1039123A1 (pt)
HR (1) HRP20010142A2 (pt)
HU (1) HUP0103228A3 (pt)
ID (1) ID27562A (pt)
IL (1) IL141239A0 (pt)
IS (1) IS5818A (pt)
MA (1) MA26680A1 (pt)
NO (1) NO20010964L (pt)
NZ (1) NZ509372A (pt)
OA (1) OA11645A (pt)
PA (1) PA8480101A1 (pt)
PE (1) PE20000986A1 (pt)
PL (1) PL346426A1 (pt)
SK (1) SK2442001A3 (pt)
SV (1) SV1999000141A (pt)
TN (1) TNSN99162A1 (pt)
TR (1) TR200101343T2 (pt)
UY (1) UY25682A1 (pt)
WO (1) WO2000012499A1 (pt)
ZA (1) ZA200101173B (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
PT1094815E (pt) * 1998-07-06 2004-04-30 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para tratamento de artropatias
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
ES2259237T3 (es) * 1998-08-27 2006-09-16 Pfizer Products Inc. Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
KR20010102073A (ko) 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2397558A1 (en) 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1322635B1 (en) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
AU2002218436A1 (en) 2000-12-19 2002-07-01 Pfizer Products Inc. Crystal forms of 6-((4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl) -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
PL208238B1 (pl) * 2001-03-12 2011-04-29 Janssen Pharmaceutica Nv Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
EP1404329A4 (en) * 2001-06-04 2006-11-02 Cytovia Inc QUINOLINONES 4-ARYL-3- (3-ARYL-1-OXO-2-PROPENYL) -2 (1H) -US SUBSTITUTED, AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS, AND RELATIVE USE
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
ATE425978T1 (de) 2001-12-19 2009-04-15 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
JP4384505B2 (ja) 2002-04-15 2009-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
JP3814285B2 (ja) * 2002-12-19 2006-08-23 ファイザー・インク 眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
EP1691812A4 (en) 2003-11-20 2010-01-13 Childrens Hosp Medical Center GTPASE INHIBITORS AND METHOD OF USE
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1784396E (pt) * 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
DK2362218T3 (en) 2004-11-05 2014-11-17 Janssen Pharmaceutica Nv Methods for monitoring the effectiveness of farnesyl transferase
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP1920048A4 (en) 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
PL2447283T3 (pl) 2005-09-07 2015-12-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
SI2056874T1 (sl) 2006-08-21 2012-12-31 F. Hoffmann-La Roche Ag Terapija tumorjev s protitelesom proti vegf
US20100184803A1 (en) * 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
ES2901506T3 (es) 2015-08-17 2022-03-22 Kura Oncology Inc Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
EP3383375A1 (en) 2015-12-03 2018-10-10 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
PT3534885T (pt) 2016-11-03 2021-04-13 Kura Oncology Inc Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP4119142A1 (en) 2017-02-21 2023-01-18 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
JP2022506463A (ja) 2018-11-01 2022-01-17 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤でがんを治療する方法
EP3897638A1 (en) 2018-12-21 2021-10-27 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20210144778A (ko) 2019-03-29 2021-11-30 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU711142B2 (en) * 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
ES2259237T3 (es) * 1998-08-27 2006-09-16 Pfizer Products Inc. Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.

Also Published As

Publication number Publication date
DE69930518T2 (de) 2006-09-21
SV1999000141A (es) 2000-07-06
CZ2001660A3 (cs) 2002-05-15
ATE321037T1 (de) 2006-04-15
HUP0103228A2 (hu) 2002-02-28
CA2341690A1 (en) 2000-03-09
KR20010072991A (ko) 2001-07-31
GEP20033001B (en) 2003-06-25
US6294552B1 (en) 2001-09-25
NO20010964L (no) 2001-04-26
IL141239A0 (en) 2002-03-10
PA8480101A1 (es) 2003-06-30
AP2001002079A0 (en) 2001-03-31
BG105365A (en) 2001-11-30
ID27562A (id) 2001-04-12
SK2442001A3 (en) 2002-10-08
AU4925499A (en) 2000-03-21
US6579887B2 (en) 2003-06-17
WO2000012499A1 (en) 2000-03-09
EE200100118A (et) 2002-06-17
CA2578326A1 (en) 2000-03-09
CA2341690C (en) 2007-04-17
BR9913138B1 (pt) 2013-11-05
HUP0103228A3 (en) 2003-01-28
CO5130017A1 (es) 2002-02-27
EA200100135A1 (ru) 2001-08-27
HK1039123A1 (zh) 2002-04-12
PE20000986A1 (es) 2000-09-30
ZA200101173B (en) 2002-04-12
DZ2880A1 (fr) 2003-12-15
CA2578326C (en) 2009-11-24
NZ509372A (en) 2003-08-29
HRP20010142A2 (en) 2002-02-28
GT199900140A (es) 2001-02-14
PL346426A1 (en) 2002-02-11
TR200101343T2 (tr) 2001-09-21
EP1107963A1 (en) 2001-06-20
DE69930518D1 (de) 2006-05-11
EP1107963B1 (en) 2006-03-22
UY25682A1 (es) 2000-03-31
MA26680A1 (fr) 2004-12-20
BRPI9913138B8 (pt) 2016-05-17
IS5818A (is) 2001-01-19
US20020128287A1 (en) 2002-09-12
TNSN99162A1 (fr) 2005-11-10
ES2259237T3 (es) 2006-09-16
NO20010964D0 (no) 2001-02-26
JP3495706B2 (ja) 2004-02-09
CN1314904A (zh) 2001-09-26
OA11645A (en) 2004-11-16
JP2002523504A (ja) 2002-07-30
US6150377A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
BR9913138A (pt) Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BR9910900A (pt) Derivados isotiazol úteis como agentes anticancerìgenos
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
TR200400342T4 (tr) Farnezil protein transferazı önlemek için kinolin türevleri.
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina
BR9910206A (pt) Derivados de higromicina a.
BR0214606A (pt) Processos para a preparação de derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BR9910232A (pt) Derivados de 2-desóxi-higromicina
BR9915813A (pt) Derivados da higromicina a como agentes antibacterianos
MX2022015986A (es) Derivados de aminopirimidinilo.
BG103985A (en) Multicyclic derivatives of erythromycin
ECSP992931A (es) Derivados de 2&#39;&#39; desoxi higromicina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: PFIZER INC. (US) , OSI PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: PFIZER PRODUCTS INC.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A PUBLICACAO NA RPI 2235 DE 05/11/2013 QUANTO AO TITULAR E TITULO.